February 2026 proved to be a pivotal month for the oncology landscape, as the FDA green-lit several therapies targeting some ...

Cabozantinib is presented as an emerging option with activity across extrapancreatic neuroendocrine tumors. Dr Lieu highlights its distinct mechanism of action and discusses how it expands treatment ...

At 125 mg palbociclib, two DLTs occurred (grade 3 anemia and grade 3 hypoxia), with no treatment-related deaths; one cerebral hemorrhage death was reported. The LITESPARK-024 trial showed a manageable ...

Antonio Ocejo, MD, discussed a multi-institutional analysis focusing on the clinical outcomes and tolerability of ipilimumab ...

This marks the first time a bispecific ADC has demonstrated a dual benefit in both PFS and OS within a phase 3 trial for TNBC ...

Gemcitabine-iDRS did not show superior bladder-intact event-free survival over chemoradiotherapy and there were no patient ...

In an interview, C. Ola Landgren, MD, PhD, delved into the details of the FDA's draft guidance on using MRD as a basis for ...

According to Tang, this independence suggests that each biomarker provides unique prognostic information, making both valuable for understanding patient outcomes. Building on these findings, the ...

During a live event, Daniel Olson, MD, discussed data and experience using tumor-infiltrating lymphocytes in melanoma.

Time to first symptomatic skeletal event, whether including or excluding death, was similar between treatment arms. Most patients did not experience skeletal complications during the follow-up period.

Actinium-225 is a targeted and highly-potent alpha emitter that holds promise for patients who do not respond to lutetium-177 ...

Dr Parikh explained that KEYNOTE-B15 (NCT04700124) is evaluating the role of perioperative enfortumab vedotin (Padcev), an ...